A detailed history of Exodus Point Capital Management, LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 262,631 shares of XENE stock, worth $10.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
262,631
Previous 357,178 26.47%
Holding current value
$10.5 Million
Previous $13.9 Million 25.75%
% of portfolio
0.06%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$36.12 - $43.96 $3.42 Million - $4.16 Million
-94,547 Reduced 26.47%
262,631 $10.3 Million
Q2 2024

Aug 13, 2024

BUY
$36.25 - $43.75 $7.36 Million - $8.89 Million
203,140 Added 131.88%
357,178 $13.9 Million
Q1 2024

May 14, 2024

SELL
$42.66 - $50.04 $8.78 Million - $10.3 Million
-205,800 Reduced 57.19%
154,038 $6.63 Million
Q3 2023

Nov 09, 2023

BUY
$34.16 - $39.73 $12.3 Million - $14.3 Million
359,838 New
359,838 $12.3 Million
Q1 2023

May 11, 2023

BUY
$33.46 - $40.35 $10.1 Million - $12.2 Million
302,980 New
302,980 $10.8 Million
Q3 2022

Nov 10, 2022

SELL
$30.79 - $39.82 $964,712 - $1.25 Million
-31,332 Closed
0 $0
Q2 2022

Aug 19, 2022

BUY
$25.44 - $35.16 $797,086 - $1.1 Million
31,332 New
31,332 $953,000
Q4 2021

Feb 11, 2022

SELL
$15.6 - $35.4 $185,109 - $420,056
-11,866 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$14.86 - $19.45 $176,328 - $230,793
11,866 New
11,866 $181,000
Q3 2020

Nov 16, 2020

SELL
$10.82 - $13.35 $215,188 - $265,504
-19,888 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.21 - $14.9 $203,056 - $296,331
19,888 New
19,888 $249,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.48B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.